Valorization of Cork Stoppers, Coffee-Grounds and Walnut Shells in the Development and Characterization of Pectin-Based Composite Films: Physical, Barrier, Antioxidant, Genotoxic, and Biodegradation Properties.

The development of sustainable materials from the valorization of waste is a good alternative to reducing the negative environmental impact of plastic packaging. The objectives of this study were to develop and characterize pectin-based composite films incorporated with cork or cork with either coffee grounds or walnut shells, as well as to test the films' genotoxicity, antioxidant properties, and biodegradation capacity in soil and seawater. The addition of cork, coffee grounds, or walnut shells modified the films' characteristics.

Assessment of the performance of the Ames MPF™ assay: A multicenter collaborative study with six coded chemicals.

The Ames MPF™ is a miniaturized, microplate fluctuation format of the Ames test. It is a standardized, commercially available product which can be used to assess mutagenicity in Salmonella and E. coli strains in 384-well plates using a color change-based readout.

Funding of research & innovation in the field of medical technologies and biomedical engineering over the different European framework programmes.

To demonstrate the role of the European Framework Programmes for Research & Innovation in supporting the field of Medical Technologies and Biomedical Engineering and to show which types of medical technologies and which funding instruments are the preferred ones. Based on data available in the European Commission data warehouse for the past two Framework Programmes, funded projects addressing a Medical Technology were identified. This enabled to categorize the projects according to the intended use and to classify into different types.

Correction to: Funding of research & innovation in the field of medical technologies and biomedical engineering over the different European framework programmes.

[This corrects the article DOI: 10.1007/s13534-023-00320-9.].

Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types.

The intestinal microbiome is by now an undebatable key player in the clinical outcome of ICI therapies. However, no microbiome profiling method to aid therapy decision is yet validated. We conducted a multi-centric study in patients with stage III/IV melanoma, NSCLC, or RCC receiving ICI treatment.